Investor behind Moderna raises $3.4bn biotech-focused fund

Fund is one of the biggest amassed in the pharmaceutical industry

The Moderna headquarters in Cambridge, Massachusetts, USA.

The Moderna headquarters in Cambridge, Massachusetts, USA.

 

Flagship Pioneering, the venture capital company behind Moderna, has raised its largest fund as it aims to build the next generation of biotech companies.

The $3.4 billion fund is one of the biggest amassed in the pharmaceutical industry and comes at a time when investment is flooding into the sector, fuelled by the numerous early-stage companies racing to make treatments and vaccines to tackle Covid-19.

Noubar Afeyan, founder of Flagship, said: “The expanded capital base is going to allow us to . . . conduct pioneering science, company creation and growth all under one roof.”

Flagship’s fund VII comprises $2.2 billion raised from investors this year and $1.2 billion raised in 2020. The company plans to deploy the cash over the next three years.

Rather than hunting for existing early-stage biotechs to finance, the Massachusetts-based group invests in developing technologies and establishing companies within its own four walls. Teams are built around specific areas of interest with the aim of spinning out to form individual companies as the research develops.

“It’s not in the traditional sense of the word an investment fund…none of what we do comes from outside,” Afeyan, who founded Flagship in 2000, told the Financial Times. “It is dedicated to advance each and every bio platform that we invent in-house.”

Flagship’s most renowned company is Moderna, which was established in 2010 with the aim of developing mRNA therapeutics, and whose chair is Afeyan. The vaccine maker sold $1.7 billion worth of Covid jabs in the first three months of the year and its share price has rocketed more than 1,000 per cent since the start of 2020.

Afeyan described Flagship’s strategy as “explorations” and “an unbounded attempt to create scientific advances coupled with product advances”. He said that developing vaccines at Moderna began by asking “if we could use a code molecule or some kind of a molecule that could instruct the body to make any drug we wanted”.

Flagship has $14.1 billion assets under management and spent $4.8 billion on its companies over the past four quarters. Last week its drug discovery business Valo Health announced it would go public by merging with a special purpose acquisition company.

Afeyan said the life sciences company does not focus on creating biotechs that will tackle specific diseases but instead looks to build platforms where technologies can be used in a range of illnesses. Moderna is currently carrying out phase 1 trials of its mRNA technology on HIV and flu.

Flagship’s scientists were particularly interested in advancing machine learning tools which can understand the human body at a more complex and granular level than humans, as well as the field of pre-emptive medicine, Afeyan said.

“Underlying health conditions made this pandemic the devastation that it was because there were all these underlying health comorbidities that made it worse,” he said. “We think we’re going to see a world in the future where we’re going to be able to intervene before diseases manifest.”

Flagship has recently expanded by opening an office in London and has hired Lord Ara Darzi, a former UK health minister, to lead its pre-emptive medicines work.– Copyright The Financial Times Limited 2021